Protein / target

Pro-opiomelanocortin

Encoded byPOMCP01189Homo sapiensSwiss-Prot

UniProt: P01189 Ensembl: ENSG00000115138 HGNC: HGNC:9201 NCBI Gene: 5443

Small-molecule tractable

Druggability

Structure with Ligand

Research papers

Protein at a glance

Biological role

Type 1 melanocortin receptor binding

Strongest disease association

Genetic Diseases, Inborn

Via encoding gene POMC · Genetic evidence · score 0.68

Research activity

Emerging research

4 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Precursor protein of pituitary hormones that are involved in diverse physiological processes, including the regulation of energy balance, stress response, immune function and skin pigmentation

Subcellular location

Secreted

Domains and Gene Ontology detail (25)

Gene Ontology

Ccytoplasm
Cextracellular region
Cextracellular space
Csecretory granule
Csecretory granule lumen
FG protein-coupled receptor binding
Fhormone activity
Fsignaling receptor binding
Ftype 1 melanocortin receptor binding
Ftype 3 melanocortin receptor binding
Ftype 4 melanocortin receptor binding
Pcalcium-mediated signaling

267 aa · 29 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

G protein-coupled signallingGO

View supporting evidence

G protein-coupled signalling

·G protein-coupled receptor binding
·positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling…

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene POMC

Gene-level evidence surfaced through the gene POMCthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Genetic Diseases, Inborn

0.68Moderately supported

Genetic evidence dominant · Open Targets 0.42

Obesity disorder

0.65Moderately supported

Animal model evidence dominant · Open Targets 0.44

Autoimmune Diseases

0.63Moderately supported

Genetic evidence dominant · Open Targets 0.38

Hair color

0.61Moderately supported

Genetic evidence dominant · Open Targets 0.37

Cardiovascular Diseases

0.52Moderately supported

Genetic evidence dominant · Open Targets 0.31

View evidence synthesis (5)

Genetic Diseases, InbornModerately supported

0.68

agreement 0.55–0.82

Genetic98%Literature2%

Open Targets aggregate 0.42 · 2 independent evidence families

Obesity disorderModerately supported

0.65

agreement 0.54–0.77

Animal model32%Pathway26%Genetic literature26%Literature15%Geneticdup

Open Targets aggregate 0.44 · 4 independent evidence families · 1 not counted as duplicate

Autoimmune DiseasesModerately supported

0.63

agreement 0.49–0.77

Genetic96%Literature4%

Open Targets aggregate 0.38 · 2 independent evidence families

Hair colorModerately supported

0.61

agreement 0.49–0.73

Genetic100%

Open Targets aggregate 0.37 · 1 independent evidence family

Cardiovascular DiseasesModerately supported

0.52

agreement 0.38–0.65

Genetic98%Literature2%

Open Targets aggregate 0.31 · 2 independent evidence families

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Obesity disorder0.44

Genetic Diseases, Inborn0.42

Autoimmune Diseases0.38

Hair color0.37

Adrenal gland disorder0.37

Cardiovascular Diseases0.31

Tractability

Small molecules — Emerging

Feasibility evidence (structure with ligand) — no clinical-stage drug of this modality recorded.

Antibodies — Emerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.